UA75325C2 - Antiparasitic derivatives of artemisin (endoperoxides) - Google Patents

Antiparasitic derivatives of artemisin (endoperoxides) Download PDF

Info

Publication number
UA75325C2
UA75325C2 UA2001021049A UA2001021049A UA75325C2 UA 75325 C2 UA75325 C2 UA 75325C2 UA 2001021049 A UA2001021049 A UA 2001021049A UA 2001021049 A UA2001021049 A UA 2001021049A UA 75325 C2 UA75325 C2 UA 75325C2
Authority
UA
Ukraine
Prior art keywords
group
general formula
compound
dihydroartemisinin
compounds
Prior art date
Application number
UA2001021049A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of UA75325C2 publication Critical patent/UA75325C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
UA2001021049A 1998-07-14 1999-07-14 Antiparasitic derivatives of artemisin (endoperoxides) UA75325C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98305596 1998-07-14
PCT/GB1999/002267 WO2000004024A1 (en) 1998-07-14 1999-07-14 Antiparasitic artemisinin derivatives (endoperoxides)

Publications (1)

Publication Number Publication Date
UA75325C2 true UA75325C2 (en) 2006-04-17

Family

ID=8234942

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2001021049A UA75325C2 (en) 1998-07-14 1999-07-14 Antiparasitic derivatives of artemisin (endoperoxides)

Country Status (27)

Country Link
US (4) US6984640B1 (da)
EP (2) EP1655302A3 (da)
JP (1) JP2002520416A (da)
KR (1) KR100640113B1 (da)
CN (1) CN1122035C (da)
AT (1) ATE314373T1 (da)
AU (1) AU765860B2 (da)
BG (1) BG105137A (da)
BR (1) BR9912810A (da)
CA (1) CA2337119A1 (da)
DE (1) DE69929203T2 (da)
DK (1) DK1095042T5 (da)
ES (1) ES2257062T4 (da)
HK (1) HK1040709B (da)
HU (1) HUP0102851A3 (da)
IL (1) IL140402A0 (da)
NO (1) NO20010223L (da)
NZ (1) NZ509324A (da)
PL (1) PL345503A1 (da)
PT (1) PT1095042E (da)
RU (1) RU2236413C2 (da)
SI (1) SI1095042T1 (da)
SK (1) SK542001A3 (da)
TR (1) TR200100073T2 (da)
UA (1) UA75325C2 (da)
WO (1) WO2000004024A1 (da)
YU (1) YU2101A (da)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2337119A1 (en) * 1998-07-14 2000-01-27 Richard K. Haynes Antiparasitic artemisinin derivatives (endoperoxides)
DE60307239D1 (de) * 2002-03-08 2006-09-14 Bayer Healthcare Ag Artemisininderivate (endoperoxide) mit wirkung gegen parasiten
DE102004027871B3 (de) 2004-06-08 2006-03-16 Lanxess Deutschland Gmbh Verfahren zur Herstellung von 10α-[4'-(S,S-Dioxothiomorpholin-1'-yl)]-10-desoxo-10-dihydroartemisinin
EP1714967A1 (en) * 2005-04-22 2006-10-25 Bayer HealthCare AG Antiparasitic artemisinin derivatives
US8431611B2 (en) 2006-10-20 2013-04-30 Johns Hopkins University Artemisinin derivatives
US8193376B2 (en) 2007-01-01 2012-06-05 Bioderm Research Artemisinin derivatives with natural amino acids, peptides, and amino sugars for the treatment of infection and topical condition in mammals
GB0720967D0 (en) * 2007-10-25 2007-12-05 Protophama Ltd Anti-material pharmaceutical composition
CA2719365C (en) * 2008-04-29 2017-03-07 Novartis Ag Spiro-indole derivatives for the treatment of parasitic diseases
ES2390046T3 (es) * 2009-04-23 2012-11-06 Londonpharma Ltd. Formulación de pulverización sublingual que comprende dihidroartemesinina
US8815942B2 (en) 2010-10-20 2014-08-26 The Royal Institution For The Advancement Of Learning/Mcgill University Combination therapy and uses thereof for treatment and prevention of parasitic infection and disease
RU2466133C1 (ru) * 2011-06-24 2012-11-10 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ НАУКИ ИНСТИТУТ ОРГАНИЧЕСКОЙ ХИМИИ им. Н.Д. ЗЕЛИНСКОГО РОССИЙСКОЙ АКАДЕМИИ НАУК (ИОХ РАН) Трициклические органические монопероксиды и способ их получения
US9675582B2 (en) 2011-10-25 2017-06-13 U.S. Phytotherapy, Inc. Alternative ACT with natural botanical active GRAS ingredients for treatment and prevention of the Zika virus
US9358261B2 (en) 2011-10-25 2016-06-07 U.S. Phytotherapy, Inc. Additional artemisinin and berberine compositions and methods of making
US9011892B2 (en) 2011-10-25 2015-04-21 U.S. Phytotherapy, Inc. Artemisinin with berberine compositions and methods of making
WO2013157005A1 (en) * 2012-04-18 2013-10-24 The Hong Kong University Of Science And Technology Methods and compositions for treating viral infections
JP5994059B2 (ja) * 2012-09-05 2016-09-21 国立大学法人東京農工大学 抗マラリア活性を有するアザアルテミシニン誘導体及びその製造方法
WO2014070673A1 (en) * 2012-10-29 2014-05-08 University Of Rochester Artemisinin derivatives, methods for their preparation and their use as antimalarial agents
WO2015041722A1 (en) 2013-09-17 2015-03-26 Kryptonite Group, Ltd Enhanced artemisinin-based combination therapy for treating parasitic mediated disease
USD729631S1 (en) 2013-10-03 2015-05-19 Gk Packaging, Inc. Bottle
USD730736S1 (en) 2013-10-03 2015-06-02 Gk Packaging, Inc. Bottle
USD729632S1 (en) 2013-10-03 2015-05-19 Gk Packaging, Inc. Bottle
USD726543S1 (en) 2013-11-04 2015-04-14 Gk Packaging, Inc. Bottle
USD727160S1 (en) 2013-11-04 2015-04-21 Gk Packaging, Inc. Bottle
USD726544S1 (en) 2013-11-04 2015-04-14 Gk Packaging, Inc. Bottle
USD726545S1 (en) 2013-11-04 2015-04-14 Gk Packaging, Inc. Bottle
CN103664982A (zh) * 2013-12-06 2014-03-26 湖南科源生物制品有限公司 青蒿素类似物及其制备方法
CN103896960A (zh) * 2014-01-14 2014-07-02 李学强 一种高效、绿色的青蒿砜制备方法
USD740125S1 (en) 2014-03-26 2015-10-06 Gk Packaging, Inc. Bottle
USD740677S1 (en) 2014-03-26 2015-10-13 Gk Packaging, Inc. Bottle
USD742748S1 (en) 2014-06-13 2015-11-10 Gk Packaging, Inc. Bottle
USD753503S1 (en) 2014-09-25 2016-04-12 Gk Packaging, Inc. Bottle
USD753502S1 (en) 2014-09-25 2016-04-12 Gk Packaging, Inc. Bottle
USD746145S1 (en) 2014-12-04 2015-12-29 GK Packaging, Inc Bottle
USD784820S1 (en) 2015-02-05 2017-04-25 Gk Packaging, Inc. Bottle
CN105198898A (zh) * 2015-09-23 2015-12-30 山东大学（威海） 一种用于预防和/或治疗癌症的化合物
USD807190S1 (en) 2015-10-13 2018-01-09 Gk Packaging, Inc. Bottle
USD784821S1 (en) 2015-10-13 2017-04-25 Gk Packaging, Inc. Bottle
USD774914S1 (en) 2015-10-13 2016-12-27 Gk Packaging, Inc. Bottle
USD806555S1 (en) 2017-03-15 2018-01-02 Gk Packaging, Inc. Bottle
IL269390B (en) 2017-03-20 2022-08-01 Broad Inst Inc Preparations and methods for the treatment of parasitic diseases
USD825342S1 (en) 2017-06-02 2018-08-14 Gk Packaging, Inc. Bottle
WO2019180708A1 (en) * 2018-03-22 2019-09-26 Hadasit Medical Research Services And Development Ltd. Methods and synergic compositions for treating viral infections
USD908011S1 (en) 2019-04-30 2021-01-19 Gk Packaging, Inc. Bottle
CN110448552B (zh) * 2019-08-23 2023-05-12 西南大学 二氢青蒿素衍生物在制备抗疟药物中的应用
CN110483547B (zh) * 2019-08-28 2022-08-16 西南大学 二氢青蒿素的简单酚类偶联物、合成方法及应用
CN110642869B (zh) * 2019-09-26 2022-03-15 西南大学 二氢青蒿素的硫醚、亚砜与砜衍生物及其应用
USD883798S1 (en) 2019-09-30 2020-05-12 Gk Packaging, Inc. Bottle
CN114276365B (zh) * 2021-12-30 2023-06-13 威胜生物医药(苏州)股份有限公司 一种蒿甲醚杂质脱水双氢青蒿素的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0362730A1 (en) * 1988-10-04 1990-04-11 Hoechst Aktiengesellschaft Artemisinin derivatives, processes for their preparation and their use as antiprotozoal agents
US5225427A (en) 1988-10-04 1993-07-06 Hoechst Aktiengesellschaft 10-substituted ether derivatives of dihydroartemisinin, process for their preparation and their use as antiprotozoal agents
CN1028294C (zh) 1989-12-21 1995-04-26 中国科学院上海药物研究所 一类含氮青蒿素衍生物的合成
TW198722B (da) 1990-05-07 1993-01-21 Hoechst Ag
US5225562A (en) * 1990-08-10 1993-07-06 Mcchesney James D Method of preparing (+)-deoxoartemisinin and selected analogues of (+)-deoxoartemisinin
WO1993008195A1 (en) * 1991-10-14 1993-04-29 The University Of Sydney Cyclic peroxyacetal compounds
JPH05203550A (ja) * 1992-01-24 1993-08-10 Shimadzu Corp 界面強度測定方法及びその測定装置
CN1049435C (zh) * 1994-11-09 2000-02-16 中国科学院上海药物研究所 含苯基和杂环基的青蒿素衍生物及其制备方法
WO1997008182A1 (en) * 1995-08-24 1997-03-06 Merck & Co., Inc. Process for the preparation of imidazolyl macrolide immunosuppressants
US6160004A (en) 1997-12-30 2000-12-12 Hauser, Inc. C-10 carbon-substituted artemisinin-like trioxane compounds having antimalarial, antiproliferative and antitumor activities
CA2337119A1 (en) * 1998-07-14 2000-01-27 Richard K. Haynes Antiparasitic artemisinin derivatives (endoperoxides)
US6649647B1 (en) 1998-07-14 2003-11-18 Richard Haynes Trioxane derivatives

Also Published As

Publication number Publication date
US6984640B1 (en) 2006-01-10
EP1095042B9 (en) 2006-07-05
EP1655302A2 (en) 2006-05-10
KR100640113B1 (ko) 2006-10-31
KR20010071899A (ko) 2001-07-31
SI1095042T1 (sl) 2006-04-30
HK1040709A1 (en) 2002-06-21
HUP0102851A3 (en) 2003-03-28
WO2000004024A1 (en) 2000-01-27
AU765860B2 (en) 2003-10-02
CN1122035C (zh) 2003-09-24
NO20010223L (no) 2001-03-12
EP1095042A1 (en) 2001-05-02
US20070021409A1 (en) 2007-01-25
ES2257062T3 (es) 2006-07-16
US7452915B2 (en) 2008-11-18
EP1095042B1 (en) 2005-12-28
HUP0102851A2 (hu) 2001-11-28
HK1040709B (zh) 2004-06-25
YU2101A (sh) 2005-06-10
US20070191354A1 (en) 2007-08-16
DK1095042T3 (da) 2006-04-18
RU2236413C2 (ru) 2004-09-20
DK1095042T5 (da) 2006-11-06
NZ509324A (en) 2003-07-25
US7439238B2 (en) 2008-10-21
ES2257062T4 (es) 2007-03-16
DE69929203T2 (de) 2006-08-31
AU4921899A (en) 2000-02-07
TR200100073T2 (tr) 2001-05-21
EP1655302A3 (en) 2006-08-23
IL140402A0 (en) 2002-02-10
BR9912810A (pt) 2001-05-02
JP2002520416A (ja) 2002-07-09
PL345503A1 (en) 2001-12-17
PT1095042E (pt) 2006-05-31
US20060287305A1 (en) 2006-12-21
DE69929203D1 (de) 2006-02-02
CN1317006A (zh) 2001-10-10
CA2337119A1 (en) 2000-01-27
SK542001A3 (en) 2001-08-06
NO20010223D0 (no) 2001-01-12
ATE314373T1 (de) 2006-01-15
BG105137A (en) 2001-08-31

Similar Documents

Publication Publication Date Title
UA75325C2 (en) Antiparasitic derivatives of artemisin (endoperoxides)
DE69000434T2 (de) Pharmazeutische zusammensetzung und verfahren zur virushemmung.
Salama et al. Evaluation of in vitro and in vivo inhibitory effects of fusidic acid on Babesia and Theileria parasites
CN105473578A (zh) 用于治疗抗药性和持续性结核病的化合物
Blagburn et al. Inhibition of Cryptosporidium parvum in neonatal Hsd:(ICR) BR Swiss miceby polyether ionophores and aromatic amidines
WO2013052263A2 (en) Antifungal compounds
JP2013506716A (ja) クロフェレマーなどのプロアントシアニジンオリゴマーを用いて疾患を治療する方法
HU201672B (en) Process for producing pharmaceutical compositions comprising podophyllotoxin
Scherler et al. Chlamydiales, Anaplasma and Bartonella: persistence and immune escape of intracellular bacteria
Giannini et al. Exploring in vitro and in vivo Hsp90 inhibitors activity against human protozoan parasites
KR100294802B1 (ko) 원충류감염의치료에유용한아토바쿠온과프로구아닐의배합물
JP2019512524A (ja) 新規使用
JPH0257523B2 (da)
EP0974594A1 (en) Artemisinin derivatives as anti-infective agent
CN102291991A (zh) 用于治疗分枝杆菌的多重耐药和广泛耐药菌株的抗菌分子
Shrestha et al. Reduced treatment frequencies with bumped kinase inhibitor 1369 are effective against porcine cystoisosporosis
US9880154B2 (en) Method for screening drugs and animal model for same
KR20200102762A (ko) 황색포도상구균 및 결핵균에 대한 항균 조성물
US20210292293A1 (en) Novel compound based on valerolactone and medicine
Lupu et al. In vitro study of diminazene aceturate complex with β-cyclodextrin for Ichthyophthirius multifiliis
MXPA01000396A (en) Antiparasitic artemisinin derivatives (endoperoxides)
EP0974354A1 (en) Artemisinin derivatives
Maykovich et al. Manzamine-A Alters In Vitro Calvarial Osteoclast Function
JP2001278787A (ja) 新規マラリア予防・治療薬